### AFTER CARDIOEMBOLIC STROKE, MAKE PREVENTION THE PRIORITY!

12:00-13:30

This session is not included in main conference CME/CPD credit

#### SYMPOSIUM IS ORGANISED AND SUPPORTED BY



12:00 - 12:05

### **INTRODUCTION AND OBJECTIVES**

H.-C. Diener, (Germany)

12:05 - 12:20

#### PFO WHERE ARE WE?

P. Rothwell, (Hong Kong PRC)

12:20 - 12:35

### PFO CLOSURE: WHO CAN BENEFIT

G. Tsivgoulis, (Greece)

12:35 - 12:45

### LIVE: DISCUSSION

D. Toni<sup>1</sup>; H.-C. Diener<sup>2</sup>; J. Nielsen-Kudsk<sup>3</sup>, (<sup>1</sup>Italy, <sup>2</sup>Germany, <sup>3</sup>Denmark)

12:45 - 12:55

### IS LAA OCCLUSION AN OPTION FOR PATIENTS WITH PRIOR ISCHEMIC STROKE?

J. Nielsen-Kudsk, (Denmark)

12:55 - 13:05

## IS LAA OCCLUSION AN OPTION FOR PATIENTS WITH PRIOR INTRACEREBRAL HEMMORHAGE?

C. Nolte, (Germany)

13:05 - 13:15

### IS LAA OCCLUSION AN OPTION FOR PATIENTS WITH MICROBLEEDS?

P. Renou, (France)

13:15 - 13:25

LIVE: DISCUSSION

D. Toni<sup>1</sup>; H.-C. Diener<sup>2</sup>; J. Nielsen-Kudsk<sup>3</sup>, (<sup>1</sup>Italy, <sup>2</sup>Germany, <sup>3</sup>Denmark)

13:25 - 13:30

LIVE: TAKE HOME MESSAGE

D. Toni, (Italy)

### AIS Therapy in 2020 – From Fundamentals to Guidelines

12:00-13:30

This session is not included in main conference CME/CPD credit

#### SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Chairs: J. Ferrari, (Austria) C. Levi, (Australia)

12:00 - 12:03

Introduction

J. Ferrari, (Austria)

12:03 - 12:19

The clot: Fundamentals and Therapeutic Implications

A. Demchuk, (Canada)

12:19 - 12:35

Is IVT needed before EVT?

M. Mazighi, (France)

12:35 - 12:51

AIS Therapy: Risk Benefit Ratio Improvement

O. Pontes-Neto, (Brazil)

12:51 - 13:07

**Imaging Techniques** 

K. Muir, (United Kingdom)

13:07 - 13:23

**Conclusion: Current Guidelines and Future Directions in AIS Therapy** 

C. Levi, (Australia)

13:23 - 13:30

Live Q&A

J. Ferrari<sup>1</sup>; A. Demchuk<sup>2</sup>; M. Mazighi<sup>3</sup>; O. Pontes-Neto<sup>4</sup>; K. Muir<sup>5</sup>; C. Levi<sup>6</sup>,

(¹Austria, ²Canada, ³France, ⁴Brazil, ⁵United Kingdom, <sup>6</sup>Australia)

## Balancing benefits versus risks for your AF patients: preventing stroke and managing consequences

12:00-13:10

This session is not included in main conference CME/CPD credit

### SYMPOSIUM IS ORGANISED AND SUPPORTED BY



Co-Chair

s: M. Grond<sup>1</sup>; R. Bernstein<sup>2</sup>

12:00 - 12:05

Welcome and introduction: our choices matter

M. Grond, (Germany)

12:05 - 12:10

LIVE Q&A

M. Grond, (Germany)

12:10 - 12:15

Why choose dabigatran for stroke prevention in patients with AF?

R. Bernstein, (United States of America)

12:15 - 12:20

LIVE Q&A

R. Bernstein, (United States of America)

12:20 - 12:25

Management of ICH and ischemic stroke: what is the role of anticoagulant reversal?

M. Grond<sup>1</sup>; A. Tomek<sup>2</sup>, (<sup>1</sup>Germany, <sup>2</sup>Czech Republic)

12:25 - 12:30

**LIVE Q&A** 

M. Grond<sup>1</sup>; A. Tomek<sup>2</sup>, (<sup>1</sup>Germany, <sup>2</sup>Czech Republic)

12:30 - 12:35

Looking beyond AF: what have we learnt from RE-SPECT CVT?

R. Lemmens, (Belgium)

12:35 - 12:40

LIVE Q&A

R. Lemmens, (Belgium)

12:40 - 13:10

Your questions answered: audience Q&A

M. Grond<sup>1</sup>; R. Bernstein<sup>2</sup>; A. Tomek<sup>3</sup>; R. Lemmens<sup>4</sup>, (<sup>1</sup>Germany, <sup>2</sup>United States of America, <sup>3</sup>Czech Republic, <sup>4</sup>Belgium)

## DOAC-Associated Intracranial Bleeds: The Challenge of Limiting Hematoma Expansion

12:30-13:30

This session is not included in main conference CME/CPD credit

## SYMPOSIUM IS ORGANISED AND SUPPORTED BY ALEXION

12:30 - 12:35

**Welcome and Introduction** 

W. Lang<sup>1</sup>; S. Schwab<sup>2</sup>, (<sup>1</sup>Austria, <sup>2</sup>Germany)

12:35 - 12:50

Unmet Need and Guideline Recommendations for Anti-FXa-Related ICH

T. Steiner, (Germany)

12:50 - 13:05

Andexanet Alfa: Clinical Data and its Relevance for Treatment of Hemorrhagic Stroke P. Kermer, (Germany)

13:05 - 13:20

Andexanet Alfa as a New Tool to Limit Hematoma Expansion

H. Huttner, (Germany)

13:20 - 13:30

**Discussion and Farewell** 

W. Lang<sup>1</sup>; S. Schwab<sup>2</sup>, (<sup>1</sup>Austria, <sup>2</sup>Germany)

How to reduce vascular risk in your patients post-stroke New data on LDL-C lowering and the effect of PCSK9 inhibitors

12:00-13:30

This session is not included in main conference CME/CPD credit

## SYMPOSIUM IS ORGANISED AND SUPPORTED BY AMGEN

Co-Chairs: G. Ntaios, (Greece) P. Amarenco, (France)

12:00 - 12:05

Raising the bar for cardiovascular risk management after stroke <u>G. Ntaios</u>, (Greece)

12:05 - 12:20

Lipid management for stroke prevention: the evidence P. Amarenco, (France)

12:20 - 12:35

PCSK9 inhibitors: LDL-C lowering and secondary stroke prevention <u>C. Gerloff</u>, (Germany)

12:35 - 12:50

Beyond trials: real-world evidence and personal experience with PCSK9 inhibitors <u>H. Milionis</u>, (Greece)

12:50 - 13:00

Identifying very-high-risk patients

G. Ntaios, (Greece)

13:00 - 13:30

Live: Panel discussion, audience Q&A and close

G. Ntaios (Greece)

Dual antiplatelet therapy for acute stroke and TIA: Current best practice and emerging strategies

12:00-13:30

This symposium accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

## SYMPOSIUM IS ORGANISED AND SUPPORTED BY RADCLIFFE CARDIOLOGY SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

AstraZeneca 2

Chair: P. Amarenco, (France)

12:00 - 12:05

Chairperson's welcome and introduction

P. Amarenco, (France)

12:05 - 12:20

Secondary prevention following acute minor stroke or TIA: Understanding the ongoing risk P. Rothwell, (Hong Kong PRC)

12:20 - 12:40

Current best practice: Evidence-based antiplatelet therapy for secondary stroke prevention P. Amarenco, (France)

12:40 - 12:55

Evolving role of dual antiplatelet therapy for stroke prevention: Advancing best practice for patients at high risk

S. Johnston, (United States of America)

12:55 - 13:10

Clinical decision making for the patient presenting with acute stroke P. Schellinger, (Germany)

13:10 - 13:25

Live Q&A

<u>P. Amarenco</u><sup>1</sup>; <u>P. Rothwell</u><sup>2</sup>; <u>S. Johnston</u><sup>3</sup>; <u>P. Schellinger</u><sup>4</sup>, (¹France, ²Hong Kong PRC, ³United States of America, ⁴Germany)

13:25 - 13:30

Summary and close

P. Amarenco, (France)

### **Stroke Care Taking Flight with The Wings of Angels**

12:00-13:30

This session is not included in main conference CME/CPD credit

### SYMPOSIUM IS ORGANISED AND SUPPORTED BY ang



Chair: W. Hacke (Germany)

12:00 - 12:15

The Angels Journey Across the World

V. Caso, (Italy)

12:15 - 12:30

Philippines: Success Is Possible Even in Challenging Environments

<u>G. Siena Mariano</u>, (Philippines), <u>R. Urgel Esagunde (</u>Philippines)

12:30 - 12:45

**Egypt: Gaining Momentum Through Simulations** 

H. Aref, (Egypt)

12:45 - 13:00

Brazil: The Next Frontier: Connecting Pre- with In-Hospital Stroke Care

S. Martins, (Brazil)

13:00 - 13:15

**Czech Republic: From Hospitals to Regions** 

R. Mikulik, (Czech Republic)

13:15 - 13:30

**Live: Question and Answer Session** 

W. Hacke<sup>1</sup>; V. Caso<sup>2</sup>; G. Siena Mariano<sup>3</sup>; H. Aref<sup>4</sup>; S. Martins<sup>5</sup>; R. Mikulik<sup>6</sup>, R. Urgel Esagunde<sup>7</sup> (1Germany, 2Italy, 3Philippines, 4Egypt, 5Brazil, 6Czech Republic, 7Philippines)

Managing anticoagulation in elderly atrial fibrillation patients with multimorbidities: acute phase and secondary prevention of stroke

12:00-13:30

This session is not included in main conference CME/CPD credit

### SYMPOSIUM IS ORGANISED AND SUPPORTED BY



12:00 - 12:10

Welcome and introduction

R. Collins, (Ireland)

12:10 - 12:30

AF patients with cerebrovascular events: management of the acute phase P. Vanacker, (Belgium)

12:30 - 12:50

Secondary stroke prevention in AF patients with multi-morbidities: evidence from clinical trials and routine care

M. Voško, (Austria)

12:50 - 13:10

Anticoagulating AF patient with a history of haemorrhagic stroke: insights from complex patient cases

M. Paciaroni, (Italy)

13:10 - 13:25

Live: Panel discussion

R. Collins<sup>1</sup>; P. Vanacker<sup>2</sup>; M. Voško<sup>3</sup>; M. Paciaroni<sup>4</sup>, (¹Ireland, ²Belgium, ³Austria, ⁴Italy)

13:25 - 13:30

**Summary and conclusion** 

R. Collins, (Ireland)

### **Transforming Stroke Care Continuum together**

12:00-13:30

This session is not included in main conference CME/CPD credit

### SYMPOSIUM IS ORGANISED AND SUPPORTED BY



### LIVE SESSION

12:00-12:40

Neurovascular:

Treatment of LVO patients with Mechanical thrombectomy.

M. Ribo<sup>1</sup>; S. Nayak<sup>2</sup>, (<sup>1</sup>Spain, <sup>2</sup>United Kingdom)

12:40-13:30

Diagnostics:

Cryptogenic Stroke: From Results to Practice – What do we do now?

Roundtable discussion

<u>L. Schwamm<sup>1</sup></u>; <u>W. Döhner<sup>2</sup></u>; <u>K. Witte<sup>3</sup></u>, (<sup>1</sup>United States of America, <sup>2</sup>Germany, <sup>3</sup>United Kingdom)